Overweight and obesity in schizophrenic patients taking clozapine compared to the use of other antipsychotics Carmen Lúcia Leitão - Azevedo

Background: The use of antipsychotics has been crucial in the treatment of schizophrenic patients. However, clozapine, as well as most atypical antipsychotics, may lead to higher weight gain and metabolic changes.Objective: To compare the frequency of overweight and obesity between schizophrenic patients exposed to clozapine to the prevalence of patients exposed to other antipsychotics.Method: This study assessed 121 schizophrenic outpatients aged 18 years or older, both genders, consecutively referred to an outpatient clinic for schizophrenia and dementia at Hospitalde Clínicas de Porto Alegre, a public hospital in Porto Alegre, Brazil. Anthropometric measures of53 patients taking clozapine and of 68 taking other antipsychotics were assessed. All patients metDSM-IV and ICD-10 diagnostic criteria for schizophrenia.Results: There was no significant difference in body mass index between schizophrenic patients taking clozapine and patients taking other antipsychotics. Analyses showed high frequencyof overweight and obesity (72.7%).Discussion: Due to higher frequency of overweight in the schizophrenic population, it was possible to confirm a higher risk of vascular and metabolic disorders in the sample. Absence of a significant difference with regard to the use of clozapine, compared to other antipsychotics,provides evidence for the need of prospective studies in order to determine the magnitude of weightgain and risk increase related to specific exposure to each antipsychotic drug.